Decline in fee income from pharmaceutical manufacturers due to a logistics-focused operating structure
First written in FY2021-Q1. 2 of 3 entries say "Restated". Latest entry: FY2021-Q3.
No other company in this theme has enough history to compare yet.
- FY2021-Q3RestatedAnnual report
「Furthermore, during the spread of COVID-19, the Group gave top priority to its social mission of ensuring a stable supply of pharmaceuticals. It suspended sales activities and supplied pharmaceuticals under a logistics-focused operating structure based on a rotating schedule. As a result, fee income from pharmaceutical manufacturers generated through sales activities declined substantially under the logistics-focused operating structure.」
It reconfirms the decline in fees from pharmaceutical manufacturers associated with the logistics-focused operating structure. - FY2021-Q2RestatedAnnual report
「As a result, fee income from pharmaceutical manufacturers generated through sales activities declined substantially under the logistics-focused operating structure.」
It reconfirms the decline in fees from pharmaceutical manufacturers associated with the logistics-focused operating structure. - FY2021-Q1First statedAnnual report
「Under the logistics-focused operating structure, fees received from pharmaceutical manufacturers through sales activities declined significantly.」
It states that the sharp decline in fee income from pharmaceutical manufacturers resulting from the suspension of sales activities to prioritize the stable supply of pharmaceuticals is a new specific risk and impact.